Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[

Nader Hirmas1, Akram Al-Ibraheem2, Ken Herrmann3

  • 1Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.

Molecular Imaging and Biology
|September 15, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is There an Added Value of Dual-Time-Point [<sup>68</sup>Ga]Ga-Fibroblast Activation Protein Inhibitor (FAPI) PET/CT in Differentiating Malignant and Benign Uptake Findings?

Cancers·2026
Same author

<sup>68</sup>Ga-FAPI Avidity in Fat Necrosis and Adrenal Adenoma: Expanding the Spectrum of Benign Pitfalls in Oncologic Imaging.

Molecular imaging and radionuclide therapy·2026
Same author

Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: A Real-World Analysis From Jordan.

JCO global oncology·2026
Same author

Utilizing [<sup>18</sup>F]-FDG PET/CT Imaging for Enhanced Staging and Treatment Decisions in Pediatric Rhabdomyosarcoma.

Cancers·2026
Same author

Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions.

World journal of nuclear medicine·2026
Same journal

Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models.

Molecular imaging and biology·2026
Same journal

Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.

Molecular imaging and biology·2026
Same journal

Preclinical Evaluation of [<sup>18</sup>F]JNJ-1: A Novel Positron Emission Tomography Ligand Targeting AMPAR/TARP γ8.

Molecular imaging and biology·2026
Same journal

Probing Early Myocardial Remodeling in Response to a High-Fat Diet in Mice by Evaluation of Extracellular Volume Fraction Using 4D Retrospectively Gated Micro-CT Imaging.

Molecular imaging and biology·2026
Same journal

Molecular Imaging of Butyrylcholinesterase Associated with Amyloid-β Plaques Distinguishes 5XFAD from Wild-Type Mice: A Proof-of-Concept.

Molecular imaging and biology·2026
Same journal

Brain Amyloid Deposition Is Negatively Associated with Cardiac Amyloid Retention in Apo E4 Carriers: A Pilot Study.

Molecular imaging and biology·2026
See all related articles

68Gallium prostate-specific membrane antigen positron emission tomography computed tomography ([68Ga]PSMA PET/CT) significantly improves staging accuracy for high-risk prostate cancer (PCa). This advanced imaging impacts patient management by better detecting lymph node and bone metastases compared to conventional methods.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Accurate staging is critical for high-risk prostate cancer (PCa) management.
  • Conventional imaging modalities (CT, MRI, bone scan) have limitations in detecting metastatic disease.
  • Novel imaging techniques are needed to improve diagnostic accuracy.

Purpose of the Study:

  • To compare the diagnostic value of [68Ga]PSMA PET/CT with CT, MRI, and bone scans for primary staging of high-risk PCa.
  • To evaluate the impact of [68Ga]PSMA PET/CT on patient management plans.

Main Methods:

  • Retrospective study including 21 patients with pathologically confirmed high-risk PCa.
  • Comparison of imaging findings from [68Ga]PSMA PET/CT, CT, MRI, and bone scans.
  • Stratification of concordance and discordance on per-patient and per-lesion bases.
Keywords:
Bone scanCT scanHigh riskMRINuclear medicinePET/CTPSMAPrimary stagingProstate cancerTheranostics

Related Experiment Videos

Main Results:

  • [68Ga]PSMA PET/CT showed higher concordance (90%) than bone scan (75%), MRI (73%), and CT (60%).
  • It demonstrated superior accuracy in detecting pelvic lymph nodes, extra-pelvic lymph nodes, and bone lesions compared to CT and bone scans.
  • [68Ga]PSMA PET/CT altered the management plan for 52% of patients.

Conclusions:

  • [68Ga]PSMA PET/CT is highly valuable for primary staging of high-risk PCa.
  • It excels in detecting lymph node spread and bone metastases, significantly influencing management decisions.
  • This modality offers improved diagnostic potential over conventional imaging.